M. Buti Et Al. , "ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)," International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL) , vol.58, Amsterdam, Netherlands, 2013
Buti, M. Et Al. 2013. ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS). International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL) , (Amsterdam, Netherlands).
Buti, M., Flisiak, R., Rasenack, J., Davis, G., Alberti, A., Goeser, T., ... Stanciu, C.(2013). ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS) . International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands
Buti, M. Et Al. "ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)," International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL), Amsterdam, Netherlands, 2013
Buti, M. Et Al. "ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)." International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL) , Amsterdam, Netherlands, 2013
Buti, M. Et Al. (2013) . "ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)." International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL) , Amsterdam, Netherlands.
@conferencepaper{conferencepaper, author={M. Buti Et Al. }, title={ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)}, congress name={International Liver Congress / 48th Annual Meeting of the European-Association-for-the-Study-of-the-Liver (EASL)}, city={Amsterdam}, country={Netherlands}, year={2013}}